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ABSTRACT
Background and the Purpose of the study: Many drug substances and variety of naturally 
occurring dietary or herbal components are capable of interaction with the CYP enzyme system. 
The aim of the study was to investigate the effect of pomegranate juice pretreatment on the 
bioavailability of buspirone in rabbits.
Methods: White New Zealand rabbits weighing 2.1±0.13 Kg were selected for study. The 
bioavailability of buspirone after pre-treatment with pomegranate juice (10 ml Kg-1 for seven 
days) was compared with an oral solution of 10 mg kg-1 of buspirone in distilled water. Animals 
were allowed free access to food and water, until night prior to dosing and were fasted for 10 
hrs. In the first phase oral solution (10 mg kg-1) was administered through feeding tube followed 
by rinsing with 10 ml of water. In the second phase, the group was pretreated with pomegranate 
juice for 7 days and study was conducted after 15 days of washout period.
Results and conclusion: The results showed that there was a significant (p<0.05) difference 
in the bioavailability of buspirone after pre-treatment with pomegranate juice.This increase in 
bioavailability might be due to inhibition of CYP3A4. Further studies are required to prove this 
mechanism in humans.
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INTRODUCTION
A variety of dietary or herbal components may 
interact  with  CYP  enzyme  system  and  induce  or 
inhibit one or more CYP iso-forms that may increase 
or decrease plasma drug concentration. The CYP3A 
family of enzymes constitutes the most predominant 
phase-I  drug  metabolizing  enzymes  estimated 
to  metabolize  between  50-70  %  of  currently 
administered drugs. CYP3A4 is the most abundant 
form which is primarily present in the hepatocytes 
and  enterocytes  (1).  Simultaneous  consumption 
of grapefruit juice with a number of therapeutic 
agents that are subject to first pass intestinal/hepatic 
metabolism have been resulted in higher plasma 
levels with subsequent adverse effects due to 
inhibition of intestinal CYP3A4 (2,3). 
Pomegranate (Punica granatum) fruits are globally 
consumed fresh and processed forms as juice, jam, 
wine,  oil  and  in  extract  supplements  (4).  They 
contain diverse range of phytochemicals polyphenols 
punicalagin  (PA),  ellagic  acid  (EA),  gallotannins, 
anthocyanins  and  other  flavonoids  (5).  PA  is  the 
most abundant of these polyphenols, and EA has 
been previously shown to exhibit anti-carcinogenic 
properties, through induction of cell cycle arrest as 
well as apoptosis and inhibition of tumor formation 
and growth in animals (6). Pomegranate has been 
used in folk medicine for a wide variety of therapeutic 
purposes. High pomegranate consumption results 
in  increased  possibility  of  pomegranate-drug 
interaction. 
Buspirone is an anxiolytic drug from the azapirone 
class of compounds (8) which undergoes extensive 
first-pass  metabolism  in  humans,  resulting  in 
a  bioavailability  of  less  than  5%,  although  it  is 
almost completely absorbed after a single oral 
administration (9,10). The metabolites of buspirone 
are mostly inactive and only oxidative dealkylation 
produces  1-(2–pyrimidinyl)-piperazine  which 
is about 20 to 25% as potent as parent drug (11). 
The aim of the present study was to investigate the 
effect of pomegranate juice pretreatment on the 
bioavailability of buspirone in rabbits.
On the basis of report on the inhibition of     CYP3A 
activity (7) by pomegranate, it appeared of interest 
to investigate the possibility of this interaction 
further.
MATERIAL AND METHODS
Buspirone  was  gifted  by  Sun  Pharmaceuticals 
266(Simvasa,  India).  Methanol  and Acetonitrile  were 
HPLC grade from E. Merck Ltd (Mumbai, India). 
All other chemicals used were of AR grade.
Methodology
Preparation of pomegranate juice
Pomegranates  (Punica granatum) were cut into 
pieces, the rind was removed and the seeds were 
grounded in mixer (Remi, Mumbai, India) and the 
freshly prepared juice was administered to rats.
In vivo bioavailability study in rabbits
The  animal  study  protocol  was  reviewed  and 
approved by the institutional animal ethical 
committee, University College of Pharmaceutical 
Sciences, Kakatiya University, India. White New 
Zealand  rabbits  weighing  2.1±0.13  Kg  were 
selected for study. The bioavailability of buspirone 
after pre-treatment with Pomegranate juice (10 ml 
Kg-1 for seven days) was compared with an oral 
solution of 10 mg kg-1 of in buspirone in distilled 
water. Animals were allowed free access to food 
and water, until night prior to dosing and fasted 
for 10 hrs. In the first phase an oral solution of 
buspirone (2.5 mg ml-1) was administered through 
feeding tube followed by rinsing with 10 ml of water. 
In  the  second  phase  the  group  was  pretreatment 
with pomegranate juice for 7 days and study was 
conducted after 15 days of washout period. Blood 
samples  (1.5  ml)  from  marginal  ear  vein  were 
collected at pre-set intervals of 0.0, 0.5, 1, 2, 4, 8, 12, 
and 24 hrs respectively, after administration of oral 
solution and also pretreatment with pomegranate 
juice. All blood samples were allowed to clot and 
centrifuged for 10 min at 4000 rpm. The serum was 
separated and transferred into clean microcentrifuge 
tubes and stored at -20° C until HPLC analysis. The 
amount of buspirone in the samples was estimated 
using HPLC (12).
Preparation of calibration curve
Primary  stock  solutions  of  each  of  buspirone 
and  diltiazem  hydrochloride  (Internal  standard) 
were prepared in methanol at a concentration of 
1.0 mg ml-1. The working solutions of 10µg ml-1 
and  1.5  µg  ml-1 were prepared by appropriately 
diluting the stock solutions of buspirone and 
diltiazem hydrochloride, respectively. Different 
concentrations  (1,  5,  10,  50,  100,  500,  1000, 
2000 and 3000 ng/ml) of buspirone in serum were 
prepared  for  calibration  curve. The  samples  were 
treated as stated in extraction procedure.  The peak 
area ratios obtained by examination of different 
concentrations of the drug and internal standard were 
plotted against the concentration of drug. The slope 
of the plot was determined by the method of least 
square regression analysis and was used to calculate 
the buspirone concentration in the unknown sample. 
The calibration curve in the range of 1-3000 ng ml-1 
resulted in the regression equation y = 0.0066x-0.1098 
(R2 = 0.9971) in serum. 
Extraction and sample preparation
Aliquot  (0.5  ml)  of  the  rabbit  serum  containing 
buspirone was pipetted into screw capped tubes 
and 100 µl of an internal standard (1500 ng ml-1 of 
internal standard) was added and vortexed for 2 min. 
Phosphate buffer (500 mM of potassium dihydrogen 
phosphate) saturated with sodium chloride solution 
of 250 µl was added, vortexed for 3 min and treated 
with 5 ml of dichloromethane. Vortexed again for 
5  min  and,  centrifuged  at  5000  rpm  for  15  min. 
The dichloromethane layer (4.5 ml) was separated 
and allowed to evaporate under vacuum oven. The 
evaporated residue was re-constituted with 150 µl of 
mobile phase and 50 µl of the re-constituted sample 
was injected in to the HPLC system.
Pharmacokinetic analysis
Pharmacokinetic  parameters  of  buspirone  before 
and after pre-treatment with pomegranate juice were 
estimated in each rabbit using a computer program, 
KINETICA 2000. Non-compartmental analysis with 
three terminal points were selected for calculation of 
the pharmacokinetic parameters Cmax, Tmax and area 
under the curve (AUC). Cmax (ng ml-1) and Tmax (h) 
were the observed maximal drug concentration and 
its time, respectively. 
 Statistical analysis
Statistical comparisons were made using Student’s 
t-test using Sigmastat software (Jandel Corp., CA, 
USA). Results were considered significant at 95 % 
confidence interval (p<0.05).
RESULTS AND DISCUSSION
All rabbits tolerated the treatments well and there 
was no case of severe adverse affects during the 
study period.  There  was  a  statistically  significant 
difference in pharmacokinetic parameters, Cmax, 
T1/2, AUC0-∞ and AUC0-24. No statistically significant 
difference  was  observed  in  Tmax pharmacokinetic 
parameter.
After  pretreatment  with  pomegranate  juice             
Cmax  increased  from  32.39±7.55  to  161.89±6.71 
ng/ml, AUC0-∞  increased  from  373.45±96.99  to 
1908.26±77.25 ng-hr/ ml. AUC0-24 increased from 
349.26±85.82 to 1708.77±49.81 ng – hr/ ml, T ½ 
increased  from  5.48±1.15  to  7.15±0.51  hrs  and 
Tmax  increased  from  1.67±0.5  to  2  hrs  (Table1  & 
Fig. 1). Pomegranate juice treatment increased the 
C  max, AUC0-∞, AUC0-24 and t1/2 by 4.99 (P<.0.001), 
5.1  (P<0.001),  4.89  (P<0.001)  and  1.4  (P<0.001) 
times  respectively.  Tmax  also increased but not 
significantly.
From the pharmacokinetic studies it appears 
that  there  is  a  statistically  significant  change  in 
AUC0-  ∞, AUC0-24, T½ and Cmax after pretreatment 
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with pomegranate juice. There was a considerable 
increase in the bioavailability of buspirone, after 
the pretreatment with pomegranate juice. This fact 
is also substantiated by the rise in Cmax value from 
32.39 to 161.89ng/ml. Though this work was carried 
out in rabbits but the same results may also be 
expected in humans. Consumption of pomegranate 
juice should be avoided when patient is on therapy 
as pomegranate juice inhibits multiple enzymes like 
CYP 3A4 and CYP 2C9. A word of caution may 
Control  R1 R2 R3 R4 R5 R6 Mean ± SD
Cmax (ng/ml) 26.5 43.5 37.5 38.4 34.3 23.6 32.39±7.5
Tmax (hr) 1.0 2.0 2.0 2.0 2.0 1.0 1.67±0.51
AUC0-24 (ng-hr/ml) 259.8 445.9 406.9 348.2 395.4 230.7 349.26±5.82
AUC0-∞ (ng -hr/ml) 280.5 470.5 448.9 358.4 444.4 239.1 373.45±96.99
T1/2 (hr) 5.9 5.1 6.5 4.1 7.0 4.4 5.48 ±1.14
Treated             
Cmax (ng/ml) 170.8 164.516 151.88 157.08 160.9 166.22 161.89±6.7
Tmax (hr) 2 2 2 2 2 2 2
AUC0-24 (ng-hr/ml) 1766.7 1687.1 1644.2 1671.8 1763.8 1712.9 1708.77±49.81
AUC0-∞ (ng -hr/ml) 1955.7 1853.11 1806.1 1886.2 2023.1 1929.4 1908.26±77.25
T1/2 (hr) 6.81 6.67 6.65 7.41 7.87 7.53 7.15±0.51
Table 1. Pharmacokinetic parameters of buspirone in control and pomegranate treated rabbits.
be advised to patients about the possible drug-fruit 
interactions and to avoid consumption of these fruits 
in large quantities during the therapy with drugs 
which are substrates of CYP3A and P-gp.
CONCLUSION 
From the results of this study it may concluded that 
pomegranate juice might be in enzyme inhibitor 
since buspirone is extensively metabolized by 
CYP3A4. 
Table 1. Pharmacokinetic parameters of buspirone in control and pomegranate treated 
rabbits
 Control   R1 R2  R3 R4 R5  R6  Mean ± SD 
Cmax (ng/ml)  26.5 43.5  37.5 38.4 34.3 23.6  32.39±7.5 
Tmax (hr)  1.0 2.0  2.0 2.0 2.0 1.0  1.67±0.51 
AUC0-24 (ng-hr/ml) 
259.8 445.9  406.9 348.2 395.4 230.7  349.26±5.82 
AUC0-∞ (ng -hr/ml)  280.5 470.5  448.9 358.4 444.4 239.1  373.45±96.99 
T1/2 (hr)  5.9  5.1  6.5  4.1  7.0  4.4  5.48 ±1.14 
Treated                   
Cmax (ng/ml)  170.8 164.516 151.88 157.08 160.9 166.22  161.89±6.7 
Tmax (hr)  2 2  2 2 2 2  2 
AUC0-24 (ng-hr/ml)  1766.7 1687.1  1644.2 1671.8 1763.8 1712.9 1708.77±49.81
AUC0-∞ (ng -hr/ml)  1955.7  1853.11 1806.1 1886.2 2023.1 1929.4  1908.26±77.25
T1/2 (hr)  6.81 6.67  6.65 7.41 7.87 7.53  7.15±0.51 
R1-R6: Different group of rabbits, Cmax-Maximum concentration in serum, Tmax- Time to reach peak serum 
concentration, AUC-Area under curve and T1/2-Elimination half life,  
Fig 1. Effect of Pomegranate juice pre-treatment on bioavailability of buspirone 
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Figure 1. Effect of Pomegranate juice pre-treatment on bioavailability of buspirone.
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